

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for medications utilizing the Universal Petition for Medication Authorization Criteria under the patient's prescription drug benefit.

Description:

The intent of the criteria is to ensure that patients follow selection elements noted in labeling and/or practice guidelines to ensure appropriate utilization for non-preferred drug list (PDL), step therapy and brand name drug requests as well as requests exceeding the PDL quantity limits.

Applicable Drug List:

Reference Oklahoma PDL

Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- The request is for a PDL product for more than the initial clinical dose or quantity limit
 OR
- The patient is unable to take required tier drug/Over-The-Counter (OTC)
 alternative(s) for the given diagnosis due to a trial and inadequate treatment
 response or intolerance, or a contraindication. Documentation is required for
 approval.
 - o If the request is for a brand name product that has a generic available on the PDL, then the patient must have had a trial and failure of the generic agent due to an adverse event (examples: rash, nausea, vomiting, anaphylaxis) that is thought to be due to an inactive ingredient

AND

 The requested product is being used for an FDA-approved indication OR an indication supported in the compendia of current literature (examples: AHFS, Micromedex, current accepted guidelines)

AND

 The prescribed dose and quantity fall within the FDA-approved labeling or within dosing guidelines found in the compendia of current literature

Note: Requests meeting these criteria can be submitted using the Universal Petition for Medication Authorization form.

Approval Duration and Quantity Restrictions:

Approval: 12 months or appropriate duration for requested drug

		* ae	etna
AETNA BETTER HEALTH®			
Coverage Policy/Guideline			
Name:	Universal Petition for Medication Authorization Criteria	Page:	2 of 2
Effective Date:	4/1/2024	Last Review Date:	10/2023
Applies to:	⊠Oklahoma		

Quantity Level Limit: Reference PDL for drug specific quantity level limits

References:

N/A